Obermatt

Chemed

NYQ:CHE · US16359R1032
Health Care Providers & ServicesLarge

360

75
EV / EBIT55
Price / Owner Earnings29
Owner Earnings Yield76
Dividend Yield91
Price/Sales11
EV / Gross Profit35
Price/Book15
Return on Capital96
Cash Return on Capital98
Return on Equity92
EBIT Margin85
Gross Profitability85
Cash Conversion34
Accruals66
Owner Earnings Margin86
Sales growth39
Profit Growth70
Long-Term EPS Growth49
Owner Earnings Growth27
Reinvestment57
Price momentum22
Debt load83
Refinancing45
Debt Payback73
Liquidity100
Analyst ratings22
Opinion Changes50
Price Target Upside28
Market mood17
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Chemed clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeLarge
TypePublic Company
ExchangeNYSE
Founded1970
Employees66
Websitechemed.com
ISINUS16359R1032
Last UpdateApr 2, 2026
Themes
Outpatient CareHome ImprovementAssisted LivingEnd-of-Life PlanningChemicalHealth CareMedical

Description

Chemed Corporation (Chemed) provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. The company provides plumbing, drain cleaning, exc…

Analysis

Quality compounder

Chemed Corporation earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is fair. The owner-earnings multiple stands at 21.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 12%. The price, in other words, assumes less than the experts do.

Growth is tepid; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Flags to be aware of: A large part of the company's book value is the price paid for past acquisitions. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
45
2023202420252026

All-time high

86

Jan 2024

All-time low

32

Nov 2024

Average rank

55

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
11
3
3
19
Price/Earnings
50
35
27
28
Price/Book
15
10
3
17
Dividend Yield
91
71
71
72
Value (overall)
40
31
25
24

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Chemed with its peers
Astrana Health
NAQ:ASTH
62
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Quest Diagnostics
NYQ:DGX
35
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Aveanna Healthcare
NSQ:AVAH
66
CountryUSA
IndustryHealth Care Providers & Services
SizeLarge
Full Stock Analysis →
McKesson
NYQ:MCK
83
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Addus
NSQ:ADUS
96
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Pennant Group
NSQ:PNTG
20
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →